DPHARMA (7148): Results for Last 10 Financial Years (Summary)

DUOPHARMA BIOTECH BERHAD

KLSE (MYR): DPHARMA (7148)

Live Data: OFF

You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!

Last Price

1.24

Today's Change

0.00 (0.00%)

Day's Change

1.22 - 1.25

Trading Volume

680,600

Financial

Market Cap

1,193 Million

NOSH

962 Million

Latest Quarter

30-Jun-2024 [#2]

Announcement Date

15-Aug-2024

Next Quarter

30-Sep-2024

Est. Ann. Date

08-Nov-2024

Est. Ann. Due Date

29-Nov-2024

QoQ | YoY

9.24% | 33.08%

Revenue | NP to SH

748,028.000 | 49,438.000

RPS | P/RPS

77.76 Cent | 1.59

EPS | P/E | EY

5.14 Cent | 24.13 | 4.14%

DPS | DY | Payout %

2.80 Cent | 2.26% | 54.48%

NAPS | P/NAPS

0.72 | 1.72

QoQ | YoY

9.16% | -28.02%

NP Margin | ROE

6.61% | 7.14%

F.Y. | Ann. Date

30-Jun-2024 | 15-Aug-2024

Latest Audited Result

31-Dec-2023

Announcement Date

26-Apr-2024

Next Audited Result

31-Dec-2024

Est. Ann. Date

26-Apr-2025

Est. Ann. Due Date

29-Jun-2025

Revenue | NP to SH

704,727.000 | 52,645.000

RPS | P/RPS

73.26 Cent | 1.69

EPS | P/E | EY

5.49 Cent | 22.66 | 4.41%

DPS | DY | Payout %

2.30 Cent | 1.85% | 42.03%

NAPS | P/NAPS

0.71 | 1.75

YoY

-24.91%

NP Margin | ROE

7.47% | 7.71%

F.Y. | Ann. Date

31-Dec-2023 | 22-Feb-2024

Revenue | NP to SH

822,584.000 | 63,932.000

RPS | P/RPS

85.51 Cent | 1.45

EPS | P/E | EY

6.64 Cent | 18.66 | 5.36%

DPS | DY | Payout %

NAPS | P/NAPS

QoQ | YoY

4.62% | -9.12%

NP Margin | ROE

7.77% | 9.23%

F.Y. | Ann. Date

30-Jun-2024 | 15-Aug-2024

Show?

YoY %

Horiz. %

	AQR	T4Q	31/12/23	31/12/22	31/12/21	31/12/20	31/12/19	31/12/18	31/12/17	31/12/16	31/12/15	31/12/14	CAGR
Last 10 FY Result
Revenue	822,584	748,028	704,727	696,717	639,175	569,902	576,462	498,722	467,987	312,940	270,680	176,961	16.58%
YoY %	9.97%	6.14%	1.15%	9.00%	12.16%	-1.14%	15.59%	6.57%	49.55%	15.61%	52.96%	-	-
Horiz. %	464.84%	422.71%	398.24%	393.71%	361.20%	322.05%	325.76%	281.83%	264.46%	176.84%	152.96%	100.00%	-
PBT	84,122	60,522	63,267	84,851	82,983	76,157	70,809	59,666	51,796	31,479	49,755	46,509	3.47%
YoY %	38.99%	-4.34%	-25.44%	2.25%	8.96%	7.55%	18.68%	15.19%	64.54%	-36.73%	6.98%	-	-
Horiz. %	180.87%	130.13%	136.03%	182.44%	178.42%	163.75%	152.25%	128.29%	111.37%	67.68%	106.98%	100.00%	-
Tax	-20,190	-11,084	-10,622	-14,739	-17,300	-17,547	-15,536	-12,025	-9,696	-4,653	0	0	-
YoY %	-82.15%	-4.35%	27.93%	14.80%	1.41%	-12.94%	-29.20%	-24.02%	-108.38%	0.00%	0.00%	-	-
Horiz. %	433.91%	238.21%	228.28%	316.76%	371.80%	377.11%	333.89%	258.44%	208.38%	100.00%	-	-	-
NP	63,932	49,438	52,645	70,112	65,683	58,610	55,273	47,641	42,100	26,826	49,755	46,509	1.38%
YoY %	29.32%	-6.09%	-24.91%	6.74%	12.07%	6.04%	16.02%	13.16%	56.94%	-46.08%	6.98%	-	-
Horiz. %	137.46%	106.30%	113.19%	150.75%	141.23%	126.02%	118.84%	102.43%	90.52%	57.68%	106.98%	100.00%	-
													-
YoY %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	-
Horiz. %	-	-	-	-	-	-	-	-	-	-	-	-	-
NP to SH	63,932	49,438	52,645	70,112	65,683	58,610	55,273	47,641	42,492	27,115	38,775	35,271	4.54%
YoY %	29.32%	-6.09%	-24.91%	6.74%	12.07%	6.04%	16.02%	12.12%	56.71%	-30.07%	9.93%	-	-
Horiz. %	181.26%	140.17%	149.26%	198.78%	186.22%	166.17%	156.71%	135.07%	120.47%	76.88%	109.93%	100.00%	-
													-
YoY %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	-
Horiz. %	-	-	-	-	-	-	-	-	-	-	-	-	-
Tax Rate	24.00%	18.31%	16.79%	17.37%	20.85%	23.04%	21.94%	20.15%	18.72%	14.78%	0.00%	0.00%	-
YoY %	31.08%	9.05%	-3.34%	-16.69%	-9.51%	5.01%	8.88%	7.64%	26.66%	0.00%	0.00%	-	-
Horiz. %	162.38%	123.88%	113.60%	117.52%	141.07%	155.89%	148.44%	136.33%	126.66%	100.00%	-	-	-
Total Cost	758,652	698,590	652,082	626,605	573,492	511,292	521,189	451,081	425,887	286,114	220,925	130,452	19.56%
YoY %	8.60%	7.13%	4.07%	9.26%	12.17%	-1.90%	15.54%	5.92%	48.85%	29.51%	69.35%	-	-
Horiz. %	581.56%	535.51%	499.86%	480.33%	439.62%	391.94%	399.53%	345.78%	326.47%	219.33%	169.35%	100.00%	-
													-
YoY %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	-
Horiz. %	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Worth	692,598	692,598	682,979	657,045	621,564	642,484	525,364	483,173	479,809	454,703	270,177	192,942	15.06%
YoY %	0.00%	1.41%	3.95%	5.71%	-3.26%	22.29%	8.73%	0.70%	5.52%	68.30%	40.03%	-	-
Horiz. %	358.97%	358.97%	353.98%	340.54%	322.15%	332.99%	272.29%	250.42%	248.68%	235.67%	140.03%	100.00%	-

	AQR	T4Q	31/12/23	31/12/22	31/12/21	31/12/20	31/12/19	31/12/18	31/12/17	31/12/16	31/12/15	31/12/14	CAGR
Dividend
Div	19,238	26,934	22,124	21,901	21,660	45,891	40,937	36,403	23,711	18,132	15,843	25,679	-1.64%
YoY %	-28.57%	21.74%	1.02%	1.11%	-52.80%	12.10%	12.46%	53.53%	30.77%	14.45%	-38.30%	-	-
Horiz. %	74.92%	104.89%	86.16%	85.29%	84.35%	178.71%	159.42%	141.76%	92.34%	70.61%	61.70%	100.00%	-
Div Payout %	30.09%	54.48%	42.03%	31.24%	32.98%	78.30%	74.06%	76.41%	55.80%	66.87%	40.86%	72.81%	-
YoY %	-44.77%	29.62%	34.54%	-5.28%	-57.88%	5.73%	-3.08%	36.94%	-16.55%	63.66%	-43.88%	-	-
Horiz. %	41.33%	74.82%	57.73%	42.91%	45.30%	107.54%	101.72%	104.94%	76.64%	91.84%	56.12%	100.00%	-

	AQR	T4Q	31/12/23	31/12/22	31/12/21	31/12/20	31/12/19	31/12/18	31/12/17	31/12/16	31/12/15	31/12/14	CAGR
Equity
Net Worth	692,598	692,598	682,979	657,045	621,564	642,484	525,364	483,173	479,809	454,703	270,177	192,942	15.06%
YoY %	0.00%	1.41%	3.95%	5.71%	-3.26%	22.29%	8.73%	0.70%	5.52%	68.30%	40.03%	-	-
Horiz. %	358.97%	358.97%	353.98%	340.54%	322.15%	332.99%	272.29%	250.42%	248.68%	235.67%	140.03%	100.00%	-
NOSH	961,942	961,942	961,942	952,239	941,765	706,026	684,383	661,881	278,959	278,959	278,959	138,807	23.98%
YoY %	0.00%	0.00%	1.02%	1.11%	33.39%	3.16%	3.40%	137.27%	0.00%	0.00%	100.97%	-	-
Horiz. %	693.01%	693.01%	693.01%	686.02%	678.47%	508.64%	493.05%	476.84%	200.97%	200.97%	200.97%	100.00%	-

	AQR	T4Q	31/12/23	31/12/22	31/12/21	31/12/20	31/12/19	31/12/18	31/12/17	31/12/16	31/12/15	31/12/14	CAGR
Ratio Analysis
NP Margin	7.77%	6.61%	7.47%	10.06%	10.28%	10.28%	9.59%	9.55%	9.00%	8.57%	18.38%	26.28%	-
YoY %	17.55%	-11.51%	-25.75%	-2.14%	0.00%	7.19%	0.42%	6.11%	5.02%	-53.37%	-30.06%	-	-
Horiz. %	29.57%	25.15%	28.42%	38.28%	39.12%	39.12%	36.49%	36.34%	34.25%	32.61%	69.94%	100.00%	-
ROE	9.23%	7.14%	7.71%	10.67%	10.57%	9.12%	10.52%	9.86%	8.86%	5.96%	14.35%	18.28%	-
YoY %	29.27%	-7.39%	-27.74%	0.95%	15.90%	-13.31%	6.69%	11.29%	48.66%	-58.47%	-21.50%	-	-
Horiz. %	50.49%	39.06%	42.18%	58.37%	57.82%	49.89%	57.55%	53.94%	48.47%	32.60%	78.50%	100.00%	-

	AQR	T4Q	31/12/23	31/12/22	31/12/21	31/12/20	31/12/19	31/12/18	31/12/17	31/12/16	31/12/15	31/12/14	CAGR
Per Share
RPS	85.51	77.76	73.26	73.17	67.87	80.72	84.49	75.35	167.76	112.18	162.30	127.49	-5.96%
YoY %	9.97%	6.14%	0.12%	7.81%	-15.92%	-4.46%	12.13%	-55.08%	49.55%	-30.88%	27.30%	-	-
Horiz. %	67.07%	60.99%	57.46%	57.39%	53.24%	63.31%	66.27%	59.10%	131.59%	87.99%	127.30%	100.00%	-
EPS	6.64	5.14	5.49	7.39	6.98	8.46	8.25	7.26	15.09	9.62	19.17	25.41	-15.64%
YoY %	29.18%	-6.38%	-25.71%	5.87%	-17.49%	2.55%	13.64%	-51.89%	56.86%	-49.82%	-24.56%	-	-
Horiz. %	26.13%	20.23%	21.61%	29.08%	27.47%	33.29%	32.47%	28.57%	59.39%	37.86%	75.44%	100.00%	-
DPS	2.00	2.80	2.30	2.30	2.30	6.50	6.00	5.50	8.50	6.50	9.50	18.50	-20.66%
YoY %	-28.57%	21.74%	0.00%	0.00%	-64.62%	8.33%	9.09%	-35.29%	30.77%	-31.58%	-48.65%	-	-
Horiz. %	10.81%	15.14%	12.43%	12.43%	12.43%	35.14%	32.43%	29.73%	45.95%	35.14%	51.35%	100.00%	-
NAPS	0.72	0.72	0.71	0.69	0.66	0.91	0.77	0.73	1.72	1.63	1.62	1.39	-7.18%
YoY %	0.00%	1.41%	2.90%	4.55%	-27.47%	18.18%	5.48%	-57.56%	5.52%	0.62%	16.55%	-	-
Horiz. %	51.80%	51.80%	51.08%	49.64%	47.48%	65.47%	55.40%	52.52%	123.74%	117.27%	116.55%	100.00%	-

	AQR	T4Q	31/12/23	31/12/22	31/12/21	31/12/20	31/12/19	31/12/18	31/12/17	31/12/16	31/12/15	31/12/14	CAGR
Adjusted Per Share Value based on latest NOSH - 961,942
RPS	85.51	77.76	73.26	72.43	66.45	59.24	59.93	51.85	48.65	32.53	28.14	18.40	16.58%
YoY %	9.97%	6.14%	1.15%	9.00%	12.17%	-1.15%	15.58%	6.58%	49.55%	15.60%	52.93%	-	-
Horiz. %	464.73%	422.61%	398.15%	393.64%	361.14%	321.96%	325.71%	281.79%	264.40%	176.79%	152.93%	100.00%	-
EPS	6.64	5.14	5.49	7.29	6.83	6.09	5.75	4.95	4.42	2.82	4.03	3.67	4.57%
YoY %	29.18%	-6.38%	-24.69%	6.73%	12.15%	5.91%	16.16%	11.99%	56.74%	-30.02%	9.81%	-	-
Horiz. %	180.93%	140.05%	149.59%	198.64%	186.10%	165.94%	156.68%	134.88%	120.44%	76.84%	109.81%	100.00%	-
DPS	2.00	2.80	2.30	2.28	2.25	4.77	4.26	3.78	2.46	1.88	1.65	2.67	-1.64%
YoY %	-28.57%	21.74%	0.88%	1.33%	-52.83%	11.97%	12.70%	53.66%	30.85%	13.94%	-38.20%	-	-
Horiz. %	74.91%	104.87%	86.14%	85.39%	84.27%	178.65%	159.55%	141.57%	92.13%	70.41%	61.80%	100.00%	-
NAPS	0.72	0.72	0.71	0.683	0.6462	0.6679	0.5461	0.5023	0.4988	0.4727	0.2809	0.2006	15.06%
YoY %	0.00%	1.41%	3.95%	5.69%	-3.25%	22.30%	8.72%	0.70%	5.52%	68.28%	40.03%	-	-
Horiz. %	358.92%	358.92%	353.94%	340.48%	322.13%	332.95%	272.23%	250.40%	248.65%	235.64%	140.03%	100.00%	-

	AQR	T4Q	31/12/23	31/12/22	31/12/21	31/12/20	31/12/19	31/12/18	31/12/17	31/12/16	31/12/15	31/12/14	CAGR
Price Multiplier on Financial Quarter End Date
Date	28/06/24	28/06/24	29/12/23	30/12/22	31/12/21	31/12/20	31/12/19	31/12/18	29/12/17	30/12/16	31/12/15	31/12/14	-
Price	1.26	1.26	1.26	1.61	1.68	3.38	1.42	0.95	2.53	1.98	2.62	2.50	-
P/RPS	1.47	1.62	1.72	2.20	2.48	4.19	1.68	1.26	1.51	1.76	1.61	1.96	-1.43%
YoY %	-9.26%	-5.81%	-21.82%	-11.29%	-40.81%	149.40%	33.33%	-16.56%	-14.20%	9.32%	-17.86%	-	-
Horiz. %	75.00%	82.65%	87.76%	112.24%	126.53%	213.78%	85.71%	64.29%	77.04%	89.80%	82.14%	100.00%	-
P/EPS	18.96	24.52	23.02	21.87	24.09	40.72	17.53	13.20	16.61	20.37	11.27	9.84	9.89%
YoY %	-22.68%	6.52%	5.26%	-9.22%	-40.84%	132.29%	32.80%	-20.53%	-18.46%	80.75%	14.53%	-	-
Horiz. %	192.68%	249.19%	233.94%	222.26%	244.82%	413.82%	178.15%	134.15%	168.80%	207.01%	114.53%	100.00%	-
EY	5.27	4.08	4.34	4.57	4.15	2.46	5.70	7.58	6.02	4.91	8.87	10.16	-9.01%
YoY %	29.17%	-5.99%	-5.03%	10.12%	68.70%	-56.84%	-24.80%	25.91%	22.61%	-44.64%	-12.70%	-	-
Horiz. %	51.87%	40.16%	42.72%	44.98%	40.85%	24.21%	56.10%	74.61%	59.25%	48.33%	87.30%	100.00%	-
DY	1.59	2.22	1.83	1.43	1.37	1.92	4.23	5.79	3.36	3.28	3.63	7.40	-14.37%
YoY %	-28.38%	21.31%	27.97%	4.38%	-28.65%	-54.61%	-26.94%	72.32%	2.44%	-9.64%	-50.95%	-	-
Horiz. %	21.49%	30.00%	24.73%	19.32%	18.51%	25.95%	57.16%	78.24%	45.41%	44.32%	49.05%	100.00%	-
P/NAPS	1.75	1.75	1.77	2.33	2.55	3.71	1.84	1.30	1.47	1.21	1.62	1.80	-0.18%
YoY %	0.00%	-1.13%	-24.03%	-8.63%	-31.27%	101.63%	41.54%	-11.56%	21.49%	-25.31%	-10.00%	-	-
Horiz. %	97.22%	97.22%	98.33%	129.44%	141.67%	206.11%	102.22%	72.22%	81.67%	67.22%	90.00%	100.00%	-

	AQR	T4Q	31/12/23	31/12/22	31/12/21	31/12/20	31/12/19	31/12/18	31/12/17	31/12/16	31/12/15	31/12/14	CAGR
Price Multiplier on Announcement Date
Date	15/08/24	15/08/24	22/02/24	23/02/23	15/02/22	22/02/21	13/02/20	18/02/19	28/02/18	24/02/17	23/02/16	24/02/15	-
Price	1.17	1.17	1.21	1.65	1.60	3.42	1.64	1.03	2.97	2.23	2.61	2.92	-
P/RPS	1.37	1.50	1.65	2.26	2.36	4.24	1.94	1.37	1.77	1.99	1.61	2.29	-3.57%
YoY %	-8.67%	-9.09%	-26.99%	-4.24%	-44.34%	118.56%	41.61%	-22.60%	-11.06%	23.60%	-29.69%	-	-
Horiz. %	59.83%	65.50%	72.05%	98.69%	103.06%	185.15%	84.72%	59.83%	77.29%	86.90%	70.31%	100.00%	-
P/EPS	17.60	22.77	22.11	22.41	22.94	41.20	20.24	14.31	19.50	22.94	11.23	11.49	7.53%
YoY %	-22.71%	2.99%	-1.34%	-2.31%	-44.32%	103.56%	41.44%	-26.62%	-15.00%	104.27%	-2.26%	-	-
Horiz. %	153.18%	198.17%	192.43%	195.04%	199.65%	358.57%	176.15%	124.54%	169.71%	199.65%	97.74%	100.00%	-
EY	5.68	4.39	4.52	4.46	4.36	2.43	4.94	6.99	5.13	4.36	8.91	8.70	-7.01%
YoY %	29.38%	-2.88%	1.35%	2.29%	79.42%	-50.81%	-29.33%	36.26%	17.66%	-51.07%	2.41%	-	-
Horiz. %	65.29%	50.46%	51.95%	51.26%	50.11%	27.93%	56.78%	80.34%	58.97%	50.11%	102.41%	100.00%	-
DY	1.71	2.39	1.90	1.39	1.44	1.90	3.66	5.34	2.86	2.91	3.64	6.34	-12.52%
YoY %	-28.45%	25.79%	36.69%	-3.47%	-24.21%	-48.09%	-31.46%	86.71%	-1.72%	-20.05%	-42.59%	-	-
Horiz. %	26.97%	37.70%	29.97%	21.92%	22.71%	29.97%	57.73%	84.23%	45.11%	45.90%	57.41%	100.00%	-
P/NAPS	1.62	1.62	1.70	2.39	2.42	3.76	2.13	1.41	1.73	1.37	1.61	2.10	-2.31%
YoY %	0.00%	-4.71%	-28.87%	-1.24%	-35.64%	76.53%	51.06%	-18.50%	26.28%	-14.91%	-23.33%	-	-
Horiz. %	77.14%	77.14%	80.95%	113.81%	115.24%	179.05%	101.43%	67.14%	82.38%	65.24%	76.67%	100.00%	-

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions

13 people like this. Showing 50 of 12,448 comments

100Mark

reaching 52 weeks low, time to grab a bit

2023-09-06 10:28

stevenckheng

noob company slowly moving a way from pharmaceutical

2023-09-06 20:25

teknikal

Support at RM1.10, if broken then RM1 is the next support

2023-09-11 09:17

fortunefire

parking here. tp 0.9x

2023-09-11 11:08

chkhooju

Moving up nicely.

2023-09-11 12:51

BobAxelrod33

Managed and operated by white haired people sitting in wheel chairs and using walking sticks. Most have prostate problems, waking few times at night to urinate. Some are waiting for stairways to Heavens........HOW COULD COMPANY BE AGGRESSIVE???

2023-10-08 13:10

MrFox

fruitcake becimes mouldy!!

2023-11-09 11:38

MagicalBobby

3Q23 profits down 45% YoY....current BOD is a team of silver haired centennials in wheelchairs. Raising 2 Billion bonds for retirement benefits?

BOD too aggressive is bad, weak BOD is also bad.......take your pick.

2023-11-10 12:07

Apastock

mari mari 1.50 yihaa ....

2023-11-10 12:55

BobAxelrod6868

You'd be lucky to even break 1.40.......

2023-11-21 07:47

BobAxelrod33

Pharma is dying, yet this ctnr with Management in wheelchairs cannot take advantage.

2023-12-02 09:04

BobAxelrod33

Max speed 2 mph......take your pick.

2023-12-04 15:13

Jettson8

not yet, it will make good performance in Q4

2023-12-06 16:38

Jettson8

it starts rebounding 😀 up up up

2023-12-15 15:38

NoTimeToTrade

This is just reaction to Covid case spike, after that fall back down. Nothing new and exciting on the horizon for pharma in the coming months especially when Pharmaniaga still in the dump and government cutting back on spending.

2023-12-15 16:03

Liner8

Great upup

2023-12-16 06:54

143922

3.00 is coming

2023-12-16 12:49

Jettson8

Dpharma is more stable and solid than those companies, fruitcake

2023-12-24 09:46

143922

Jual je la sykt GLC ni.epf pun tak mau beli ticket.kannaya

2023-12-31 09:31

Jettson8

Hope this collaboration can bring good revenue to the company for Fy2024 and so on

https://theedgemalaysia.com/node/692365

2024-01-15 17:14

100Mark

See, Kwsp was buying in. I think it can 😄

2024-01-22 17:34

Jettson8

Ya, even TA securities raised its target price to Rm1.47

2024-01-26 15:41

100Mark

Duopharma Biotech Bhd is likely to see a recovery in its consumer healthcare (CHC) segment, while sales to the government sector is also expected to increase in 2024.

https://www.thestar.com.my/business/business-news/2024/01/26/duopharma-earnings-set-to-improve-this-year

2024-01-30 17:36

metaverse

This is my trading call dated 15 Dec 2020. Most of the time chart will tell the true story:

https://www.tradingview.com/chart/DPHARMA/5tKe08jN-Trend-Analysis/

For investment or trading ideas, please feel free to visit my chart gallery:

https://www.tradingview.com/u/Yang358/#published-charts

2024-01-31 17:43

100Mark

@metaverse. What did you use for that technical analysis?

2024-02-02 16:19

metaverse

I love astronomy so most of my calculation/logics actually somehow related to astrophysics and planetary orbit. Something to do with price resistance, time resistance and speed resistance.

2024-02-02 16:45

MrFox

fruitcake turns mouldy?

2024-02-21 11:40

Meshach Mano

Starting its journey to 1.4 soon

2024-05-01 18:43

cyberzigot

Limit up

2024-05-02 09:08

Mar2083

Afternoon sessions limit up
Huat ar

2024-05-02 09:12

NoTimeToTrade

Duopharma Biotech Clinches MYR578 million Supply Deals

https://www.tradingview.com/news/mtnewswires.com:20240501:G2361746:0/

2024-05-02 09:21

jenabchen123

Yuhoo!!! Finally Duo making big move. 1.40 seems reasonable figure to relief breath.

2024-05-02 19:09

Mar2083

Potentially may test 1. 4 tomorrow

2024-05-02 21:53

jenabchen123

Ayo!!! What has 600m contract do to the Duo's share price??? Sometime the illogical happen.....

2024-05-04 18:39

Jettson8

Keep & follow TP from OSK

https://klse.i3investor.com/web/pricetarget/research/71461

2 months ago

Jettson8

or you are more fond of pharmaniaga, fruitcake 😁

2 months ago

Jettson8

That is 1-year low price for Dpharma dude

fruitcake

1.10 please

19 hours ago

2 months ago

Jettson8

A+ for your patience 😆

2 months ago

NoTimeToTrade

Haha unfortunately i'm closing my position with Dpharma, feels like watching paint dry. Anyways good luck guys.

1 month ago

Jettson8

I am pretty sure you made a good profit from it, NoTimeToTrade 😉

1 month ago

Jettson8

I think they have. https://www.freemalaysiatoday.com/category/nation/2016/01/28/viagra-no-longer-hard-to-get/

1 month ago

100Mark

Oww...EPF is throwing this moth

1 month ago

100Mark

EPF switched to another counters like CTOS, KLK, ...

1 month ago

Jettson8

no worries, Duopharma still hanging strong

1 month ago

fruitcake

will be very hard for dumpharma to go beyond here this year. believe me😁

3 weeks ago

100Mark

Ya, it will only move back and forth at 1.20 - 1.30

3 weeks ago

fruitcake

testing 1.20. bearish indicators. run or no run😱

3 weeks ago

100Mark

IF urgently need the money, then better run

3 weeks ago

100Mark

The market will become very 'interesting' tmr

2 weeks ago

Jettson8

Duopharma Biotech 2Q net profit up 33%, pays one sen dividend 🔥

https://theedgemalaysia.com/node/722957

1 week ago

Featured Posts

MQ Trader

Introducing MY's First IPO Fund for Sophisticated Investors!

MQ Chat

New Update. Discover investment communities that resonate with your ideas

MQ Trader

M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a

Latest Videos